(Q24203739)

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Randomized pilot study of nimesulide treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Long-term efficacy and safety of celecoxib in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Treatment of the mild cognitive impairment (MCI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Indomethacin and cognitive function in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of high-dose cortisol on memory functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

NSAIDs and cognition in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Dexibuprofen (S(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Nonsteroidal antiinflammatory drug use in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

The Effect of Mifepristone (RU 486) on Plasma Cortisol in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effects of an ACTH/MSH(4-9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?--Results of a representative survey in lower Saxony, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

The role of inflammation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cyclooxygenase-2: a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Pharmaceutical prospects of phytoestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Reversible impaired memory induced by pulsed methylprednisolone in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Protective effects of NSAIDs on the development of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with R-Flurbiprofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Protection against stroke and dementia: an update on the latest clinical trial evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Inflammatory mechanisms in Alzheimer's disease: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Glucocorticoids in Alzheimer's disease. The story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Alzheimer Disease in the US Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

The incidence of dementia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Alzheimer's disease. In the beginning...

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Evidence that A beta 42 is the real culprit in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Association of chronic non-steroidal anti-inflammatory drugs use and cognitive decline in non-demented elderly patients admitted to a geriatric evaluation and rehabilitation unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

An estimate of the total worldwide societal costs of dementia in 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Selective Cox-2 inhibition in man-therapeutic breakthrough or cosmetic advance?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Clinical trial designs for demonstrating disease-course-altering effects in dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Medication use as a risk factor for falls among hospitalized elderly patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006378.PUB2

7 January 2021

10.1002/14651858.CD006378.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22336816

1 reference

Consolidated OpenCitations Corpus – April 2017